BiotechTube
Antagonis Biotherapeutics

Antagonis Biotherapeutics

Vienna, Austria· Est.
antagonis.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4.5M

Overview

Antagonis Biotherapeutics is an early-stage Austrian biotech pioneering a novel approach to targeting glycosaminoglycans (GAGs)—a challenging class of polysaccharides involved in cancer metastasis and other diseases. The company's core asset is its GAGbody™ platform, which engineers natural GAG-binding proteins into therapeutic proteins with extended half-life, aiming to block pro-metastatic chemokine signaling. With a lead candidate showing efficacy in a murine metastasis model, Antagonis is positioned as both a platform company and a therapeutics developer, actively seeking partnerships to advance its pipeline. The company benefits from a strong academic foundation at the University of Graz and an experienced leadership team with backgrounds in drug discovery and biologics development.

OncologyImmuno-oncology

Technology Platform

GAGbody™ platform: A proprietary system for engineering protein-based glycan antagonists. It utilizes the GlycAffibase™ (database of 5500+ GAG-binding proteins), a human GAG oligosaccharide library for screening, ELICO technology for specificity testing, and protein scaffolding for half-life extension.

Funding History

1
Total raised:$4.5M
Seed$4.5M

Opportunities

The GAGbody™ platform addresses the previously 'undruggable' target class of glycosaminoglycans, opening a new frontier in immuno-oncology by specifically targeting metastasis.
The platform's modularity also creates significant partnering potential for applications in fibrosis, neurodegeneration, and cardiovascular diseases.
Successfully inhibiting metastasis could meet a massive unmet medical need and capture a substantial share of the growing cancer therapeutics market.

Risk Factors

Major scientific risk exists in achieving therapeutic specificity for ubiquitous GAG targets without causing intolerable side effects.
As a pre-clinical, private company, Antagonis faces significant funding and operational risks, including dependence on future capital raises and partnership deals.
The highly competitive immuno-oncology landscape presents commercial risks from alternative approaches developed by larger, better-resourced companies.

Competitive Landscape

Antagonis operates in a niche with few direct competitors targeting GAGs with protein-based therapeutics. However, it competes indirectly with numerous companies developing small molecule or antibody-based approaches to inhibit metastasis, chemokine signaling, and tumor microenvironment interactions. Its primary competitive advantage is its first-mover platform technology and deep glycobiology expertise, but it faces competition from larger biopharma with greater clinical development and commercialization capabilities.

More companies in Biologics / Biosimilars →More companies in Austria →